## ABVX: Abivax SA - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 3.8% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($110.72)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 2
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Abivax Sees Unusually Large Options Volume (NASDAQ:ABVX)**
- Source: MarketBeat | 20251209T160928 | Bullish | Relevance: 98%
-  Abivax (NASDAQ:ABVX) experienced unusually large options trading volume on Tuesday, with traders purchasing 3,575 call options, an 82% increase over the daily average. This activity comes as analysts have raised price targets and ratings, with a consensus "Moderate Buy" rating and an average target of $123. The clinical-stage biotech is advancing its lead drug obefazimod in Phase 3 trials for ulcerative colitis, and its shares traded up about 5.9% to $121.85 amid the increased interest.

**2. Abivax SA Sponsored ADR $ABVX Shares Acquired by Kennedy Capital Management LLC**
- Source: MarketBeat | 20251208T111009 | Bullish | Relevance: 98%
-  Kennedy Capital Management LLC increased its stake in Abivax SA Sponsored ADR (NASDAQ:ABVX) by 7.1% during the second quarter, now owning 241,188 shares valued at $1.85 million. Several other institutional investors also increased their holdings, bringing total institutional ownership to 47.91%. Analysts currently rate Abivax with a "Moderate Buy" and an average target price of $123.00, while the company's lead drug candidate, obefazimod, is in Phase 3 trials for ulcerative colitis.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-24 | Truist Securiti | $140 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-24 | Truist Securiti | init | Buy |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 34.6% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- TCG Crossover Manage: 9.1% (+17.4%)
- UBS Group AG: 5.7% (+2561.0%)
- Darwin Global Manage: 4.1% (+100.0%)
- Point72 Asset Manage: 3.8% (+1642.4%)
- Cormorant Asset Mana: 2.5% (-8.5%)

### Key Risks

1. Market regime shift could impact momentum names disproportionately.
2. Sector rotation risk if leadership changes from current market theme.
3. Earnings execution risk on next quarterly report.

### Catalysts

- Momentum building: MRS_20 improving +8.0% over 5 days suggests accumulation.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

Revenue growth strong at 721% YoY. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $9.6B |
| Beta | -0.11 |
| 52W Range | $4.77 - $130.25 |
| Short Interest | 2.7% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 strengthening from -4.2% to 3.8% (+8.0% in 5 days), confirming momentum buildup. Below STRENGTH zone by 0.2pp (needs >4.0% for momentum thesis). MRS_5 at 7.0% confirms short-term momentum alignment. AM_20 at 6.1% shows strong absolute momentum above own 20MA. Outperforming sector by 8.3pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram bearish (-1.06), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 3.78% (CS: 79) | Neutral |
| RSI_14 | 62.5 | Neutral |
| MACD Histogram | -1.06 | Bearish |
| vs SMA20 | 1.061x | Above |
| vs SMA50 | 1.198x | Above |
| vs SMA200 | 2.576x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $123.04
- **Stop Loss:** $110.72 (10.0% risk)
- **Target:** $135.36 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 24
- **Position Value:** $2,952.96
- **Portfolio %:** 2.95%
- **Risk Dollars:** $300.00
- **Risk Per Trade:** 0.30%
- **Modifiers:** L1 100% | L2 25% | Combined 0.30x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | TOXIC (Zone G) | 0.25x |

*NORMAL regime with moderate risk appetite. VIX remains in the mid-range, breadth is moderate, and yield curve is flat but not invertedâ€”indicating standard late-cycle conditions. Upbeat earnings and positive tech momentum are offset by cautious guidance in consumer sectors, suggesting selective positioning is favored.*

### Earnings

**Next:** 2026-03-23 (Est: $0.00)

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*